$OTLC
Oncotelic Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000119312519147291 Filed on May 15, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $800.0K $570.0K $510.0K
YoY Change 33.33% -8.06% -22.73%
% of Gross Profit
Research & Development $360.0K $135.0K $120.0K
YoY Change 5.26% -40.0% -93.22%
% of Gross Profit
Depreciation & Amortization $30.00K $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $1.160M $634.0K $630.0K
YoY Change 29.18% -20.25% -74.18%
Operating Profit -$634.0K
YoY Change -20.25%
Interest Expense -$30.00K $0.00 $0.00
YoY Change -111.54%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$1.190M -$980.0K -$630.0K
YoY Change 85.94% 24.05% -74.07%
Income Tax
% Of Pretax Income
Net Earnings -$1.190M -$633.0K -$630.0K
YoY Change 85.36% -20.28% -74.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.02 -$0.02 -$0.02
COMMON SHARES
Basic Shares Outstanding 82.10M 41.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.00K $200.0K $630.0K
YoY Change -95.94% -13.04% -43.75%
Cash & Equivalents $80.00K $200.0K $629.0K
Short-Term Investments
Other Short-Term Assets $100.0K $140.0K $170.0K
YoY Change 0.0% -17.65% 750.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $190.0K $340.0K $799.0K
YoY Change -90.8% -15.84% -29.73%
LONG-TERM ASSETS
Property, Plant & Equipment $50.00K
YoY Change
Goodwill $4.900M
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.770M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $7.470M $51.00K $0.00
YoY Change 22536.36% 54.55% -100.0%
TOTAL ASSETS
Total Short-Term Assets $190.0K $340.0K $799.0K
Total Long-Term Assets $7.470M $51.00K $0.00
Total Assets $7.660M $391.0K $799.0K
YoY Change 264.94% -10.53% -31.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.580M $901.0K $915.0K
YoY Change 29.4% -22.59% 16.12%
Accrued Expenses $230.0K $270.0K $250.0K
YoY Change -32.35% -25.0% -70.93%
Deferred Revenue
YoY Change
Short-Term Debt $230.0K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.040M $1.174M $1.161M
YoY Change 30.69% -22.97% -29.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.040M $1.174M $1.161M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.040M $1.170M $1.160M
YoY Change 30.77% -23.03% -29.7%
SHAREHOLDERS EQUITY
Retained Earnings -$295.6M -$295.0M
YoY Change 0.88% 0.94%
Common Stock $294.9M $294.7M
YoY Change 0.99% 0.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.620M -$783.0K -$362.0K
YoY Change
Total Liabilities & Shareholders Equity $7.660M $391.0K $799.0K
YoY Change 264.94% -10.53% -31.83%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$1.190M -$633.0K -$630.0K
YoY Change 85.36% -20.28% -74.07%
Depreciation, Depletion And Amortization $30.00K $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$460.0K -$429.0K -$420.0K
YoY Change -26.98% -51.36% -46.84%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $180.0K $0.00 $0.00
YoY Change
Cash From Investing Activities $180.0K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 790.0K 0.000 0.000
YoY Change -66.53%
NET CHANGE
Cash From Operating Activities -460.0K -429.0K -420.0K
Cash From Investing Activities 180.0K 0.000 0.000
Cash From Financing Activities 790.0K 0.000 0.000
Net Change In Cash 510.0K -429.0K -420.0K
YoY Change -70.52% -51.36% -46.84%
FREE CASH FLOW
Cash From Operating Activities -$460.0K -$429.0K -$420.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-633000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-794000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41420000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
184000
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-88000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-125000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-429000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-882000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
629000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1115000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200000
CY2019Q1 us-gaap Assets
Assets
391000
CY2018Q4 us-gaap Assets
Assets
799000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
340000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
799000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
901000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
915000
CY2019Q1 matn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
27000
CY2018Q4 matn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
27000
CY2019Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
49000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
24000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
391000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
799000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
294448000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
294236000
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
414000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
414000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1174000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1161000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
43000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
69000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295645000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295012000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-783000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-362000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-634000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-795000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
225000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
499000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
570000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-633000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-794000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-429000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-882000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
233000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
629000
CY2019Q1 matn Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
140000
CY2018Q4 matn Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
170000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2465000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6785000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.75
CY2019Q1 matn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
11000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
634000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
795000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11000
CY2018Q1 us-gaap Depreciation
Depreciation
2000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
212000
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.78
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2476000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6774000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.74
CY2019Q1 matn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P6Y10M24D
CY2019Q1 matn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
4335000
CY2019Q1 matn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
0.72
CY2019Q1 matn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P6Y10M24D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6461000
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2439000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.59
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.78
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
366000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
51000
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
99000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
126000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
55000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41420000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41420000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41420000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41420000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-477000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-794000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
184000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-1087000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-633000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
212000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; line-height: 12pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 6pt; text-indent: 0.79in;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S.&#160;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22216000
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
24381000
CY2019Q2 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock and is eligible to vote on stockholder matters on an as-converted basis. The Series A Preferred Stock will convert into common stock upon the availability of a sufficient number of authorized shares of common stock.
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2019Q1 matn Cash Equivalents Maturity Description
CashEquivalentsMaturityDescription
three months or less
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82100664
CY2019Q1 matn Increase Decrease In Prepaid Expenses Other Current Assets And Right Of Use Operating Assets
IncreaseDecreaseInPrepaidExpensesOtherCurrentAssetsAndRightOfUseOperatingAssets
-80000
CY2018Q1 matn Increase Decrease In Prepaid Expenses Other Current Assets And Right Of Use Operating Assets
IncreaseDecreaseInPrepaidExpensesOtherCurrentAssetsAndRightOfUseOperatingAssets
149000
CY2019Q1 us-gaap Cash
Cash
200000
CY2019Q2 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
540000
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
112000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
56000
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000908259
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
MATEON THERAPEUTICS INC
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
MATN
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 matn Initial Recognition Of Right Of Use Operating Assets
InitialRecognitionOfRightOfUseOperatingAssets
101000
CY2019Q1 matn Initial Recognition Of Facility Lease Obligations
InitialRecognitionOfFacilityLeaseObligations
109000

Files In Submission

Name View Source Status
0001193125-19-147291-index-headers.html Edgar Link pending
0001193125-19-147291-index.html Edgar Link pending
0001193125-19-147291.txt Edgar Link pending
0001193125-19-147291-xbrl.zip Edgar Link pending
d674011d10q.htm Edgar Link pending
d674011dex311.htm Edgar Link pending
d674011dex312.htm Edgar Link pending
d674011dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
matn-20190331.xml Edgar Link completed
matn-20190331.xsd Edgar Link pending
matn-20190331_cal.xml Edgar Link unprocessable
matn-20190331_def.xml Edgar Link unprocessable
matn-20190331_lab.xml Edgar Link unprocessable
matn-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending